Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES
Jeffrey S. Heier, Rishi P. Singh, Charles C. Wykoff, et al.
Retina (2020) Vol. 41, Iss. 1, pp. 1-19
Open Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
Jeffrey S. Heier, Arshad M. Khanani, Carlos Quezada-Ruiz, et al.
The Lancet (2022) Vol. 399, Iss. 10326, pp. 729-740
Open Access | Times Cited: 440
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
Charles C. Wykoff, Francis Abreu, Anthony P. Adamis, et al.
The Lancet (2022) Vol. 399, Iss. 10326, pp. 741-755
Open Access | Times Cited: 302
Faricimab: First Approval
Matt Shirley
Drugs (2022) Vol. 82, Iss. 7, pp. 825-830
Open Access | Times Cited: 106
Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration
Levon M. Khachigian, Gerald Liew, Kelvin Yi Chong Teo, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 50
Faricimab Treat-and-Extend for Diabetic Macular Edema
Tien Yin Wong, Zdenka Hašková, Kemal Asik, et al.
Ophthalmology (2023) Vol. 131, Iss. 6, pp. 708-723
Open Access | Times Cited: 46
Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis
Lei Wang, Wang‐Qing Liu, Sylvain Broussy, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 40
Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion
Ramin Tadayoni, Liliana P Paris, Carl J. Danzig, et al.
Ophthalmology (2024) Vol. 131, Iss. 8, pp. 950-960
Open Access | Times Cited: 25
Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration
Benjamin Ng, Hema Kolli, Naduviledeth Ajith Kumar, et al.
Life (2024) Vol. 14, Iss. 2, pp. 193-193
Open Access | Times Cited: 18
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins
Marlena Surowka, Wolfgang Schaefer, Christian Klein
mAbs (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 60
Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration
Reem H. ElSheikh, Muhammad Z. Chauhan, Ahmed B. Sallam
Biomolecules (2022) Vol. 12, Iss. 11, pp. 1629-1629
Open Access | Times Cited: 54
A Linkage between Angiogenesis and Inflammation in Neovascular Age-Related Macular Degeneration
Hanna Heloterä, Kai Kaarniranta
Cells (2022) Vol. 11, Iss. 21, pp. 3453-3453
Open Access | Times Cited: 51
An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma
Faruque Ghanchi, Rupert Bourne, Susan M. Downes, et al.
Eye (2022) Vol. 36, Iss. 6, pp. 1154-1167
Open Access | Times Cited: 45
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration
Keiko Kataoka, Kanako Itagaki, Nozumu Hashiya, et al.
Graefe s Archive for Clinical and Experimental Ophthalmology (2023) Vol. 262, Iss. 1, pp. 43-51
Closed Access | Times Cited: 33
Clinical Outcomes Following a Switch of Therapy to Faricimab in Patients Affected by Neovascular Age-Related Macular Degeneration
Peter Wolfrum, Elsa Wilma Böhm, Katrin Lorenz, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 423-423
Open Access | Times Cited: 1
Diabetic macular ischaemia- a new therapeutic target?
Chui Ming Gemmy Cheung, Amani A. Fawzi, Kelvin Yi Chong Teo, et al.
Progress in Retinal and Eye Research (2021) Vol. 89, pp. 101033-101033
Open Access | Times Cited: 54
The emerging role of the Angiopoietin-Tie pathway as therapeutic target for treating retinal diseases
Lorenzo Ferro Desideri, Carlo Enrico Traverso, Massimo Nicolò
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 2, pp. 145-154
Closed Access | Times Cited: 30
Evolving treatment paradigms for PCV
Beau J. Fenner, Chui Ming Gemmy Cheung, Shaun Sebastian Sim, et al.
Eye (2021) Vol. 36, Iss. 2, pp. 257-265
Open Access | Times Cited: 37
Optical coherence tomography in the management of diabetic macular oedema
Simon Szeto, Timothy Y. Y. Lai, Stela Vujosevic, et al.
Progress in Retinal and Eye Research (2023) Vol. 98, pp. 101220-101220
Closed Access | Times Cited: 15
Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials
Kanji Takahashi, Chui Ming Gemmy Cheung, Tomohiro Iida, et al.
Graefe s Archive for Clinical and Experimental Ophthalmology (2023) Vol. 261, Iss. 11, pp. 3125-3137
Open Access | Times Cited: 14
One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan
Ryo Mukai, Keiko Kataoka, Koji Tanaka, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Short-term outcomes of intravitreal faricimab for refractory neovascular age-related macular degeneration
Wissam Al-Jundi, Cristian Munteanu, Berthold Seitz, et al.
Graefe s Archive for Clinical and Experimental Ophthalmology (2024) Vol. 262, Iss. 9, pp. 2867-2874
Closed Access | Times Cited: 5
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial
Masahiko Shimura, Shigehiko Kitano, Nahoko Ogata, et al.
Japanese Journal of Ophthalmology (2023) Vol. 67, Iss. 3, pp. 264-279
Open Access | Times Cited: 13
Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review
Nasratullah Nasimi, Safiullah Nasimi, Jakob Grauslund, et al.
International Journal of Retina and Vitreous (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 4
Persistence of Retinal Fluid after Anti-VEGF treatment for neovascular age-related macular degeneration: A Systematic Review and Meta-Analysis
Dominic Wei Ting Yap, Benjamin Kye Jyn Tan, Kelvin Yi Chong Teo, et al.
Ophthalmology Retina (2025)
Open Access
Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema
Jennifer I. Lim, Manuel Amador, Dilsher S. Dhoot, et al.
Ophthalmology Retina (2025)
Closed Access
Page 1 - Next Page

Scroll to top